Logo
homeHome
toggle_offCompany ProfilegroupsBoards & Staffsworkspace_premiumMemberships & PartnersschoolAcademy of Journalismperson_addCareerslinkBlog(EN)emailContact Us
list_altOur JournalslightbulbInstruction for AuthorsbookmarkBrieflands PolicieshandshakePublish My Researchplay_circleJournal Management Systemcredit_cardArticle Processing Chargeszoom_inOpen Peer ReviewimagePublishing Services
menu_bookPublish My Book

International Journal of Cancer Management

The Official Journal of Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences

homeHome
play_circleCurrent IssuelistAll Issuesformat_indent_increaseIn Press Articlescheck_circleAccepted ManuscriptssearchSearch
settingsInstructions
infoJournal InformationgroupsBoards and CommitteesshareIndexing and Listing Sourcesshow_chartJournal Metricszoom_inOpen Peer Review (OPR)balancePublication Ethics and Malpractice Statementmenu_bookReviewer and AE Registration FormcampaignAnnouncementemailSupportphoneContact Us
format_list_bulletedAPC
Authors GuideSubmit Manuscript

Scopus by Title (Ref)

1. New Substituted 6,7-Dimethoxy-N-phenyl-2-(piperazin-1-yl)quinazolin-4-amine Derivatives: Synthesis, Characterization, Cytotoxicity against SKBR3 and Trastuzumab Resistance SKBR3 Cell Lines, and EGFR/HER2 Dual Kinase Inhibition Assay

- Bakshi V. , et al.

2. Exploring Bevacizumab's Role in Gynecological Cancers: An Up-to-Date Narrative Review Focusing on Ovarian Cancer

- Liolis E. , et al.

3. Anti-rituximab antibodies in patients with refractory autoimmune nodopathy with anti-neurofascin-155 antibody

- Bai Y. , et al.

4. Anti-drug antibodies in the current management of cancer

- Borregón M. , et al.

5. Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequences

- Saffari F. , et al.

6. Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis

- Bar-Or A. , et al.

7. Managing the Impact of Immunogenicity in an Era of Immunotherapy: From Bench to Bedside

- Bray-French K. , et al.

8. The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies

- Vaisman-Mentesh A. , et al.